CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: GlobeNewswire
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose- -Among participants with elevated baseline TG (150 mg/dL), a mean reduction of 60% in TG were observed at therapeutic doses- -CTX310 was well tolerated with no treatment-related serious adverse events and no =Grade 3 changes in liver transaminases- -Findings simultaneously published in The New England Journal of Medicine entitled “First-in-Human Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3”- ZUG, Switzerland and BOSTON, Nov. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on crea
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]Seeking Alpha
- CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]Seeking Alpha
- What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- CRSP's page on the SEC website